TITLE:
The Use of FOLFOX4 Regimen in Stage IV Cervical Cancer: A Pilot Study
AUTHORS:
Ekkasit Tharavichitkul, Ekkapong Tharavichitkul, Somvilai Chakrabandhu, Pitchayaponne Klunklin, Wimrak Onchan, Bongkot Supawongwattana, Nantaka Pukanhaphan, Imjai Chitapanarux
KEYWORDS:
Cervical Cancer, FOLFOX4, Metastasis
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.7 No.4,
April
28,
2016
ABSTRACT: Objective: To evaluate the efficacy and safety of FOLFOX4
(oxaliplatin/5FU/Leucovorin) for the treatment of metastatic cervical cancer.
Methods: All patients were designed to receive the FOLFOX4 regimen (Oxaliplatin
(Eloxatin®) 85 mg/m2 D1, 5-Fluorouracil 400 mg/m2 IV push D1-2, 5-Fluorouracil 600 mg/m2 IV drip in 22 hours D1-2 and
Folinic acid 200 mg/m2 IV push in D1-2). The treatment
responsiveness and toxicities were evaluated. Results: Thirty patients from
January 2010-December 2012 were enrolled into the study. The mean age was 51
years old. Nine patients (31%) achieved objective response. At the mean
follow-up time of 13 months, the one-year progression-free and overall survival
rates were 20.7% and 65.5%, respectively. The most common grade 3 adverse event
reported in this study was anemia (36.7%), thrombocytopenia (16.7%) and fatigue
(16.7%). Conclusions: FOLFOX4 regimen in metastatic cervical cancer is
feasible.